2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2449 Total marrow irradiation-based conditioning for single-unit unrelated cord blood transplantation in refractory/relapsed aplastic anemia: A prospective, single-center, open-label clinical trial

Yuan Li, Erling Chen2, Hong Pan3, Chenhui Luo, MD4, Yanping Ji, MS5, Xin Zhao, MD6, Jianxiang Wang Sr, MD, PhD7, Zimin Sun, MD8
1 Regenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center For Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Scienc, Tianjin, China
2 Regenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center For Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Scienc, Tianjin, China
3 Regenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center For Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Scienc, Tianjin, China
4 Regenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center For Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Scienc, Tianjin, China
5 Regenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center For Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Scienc, Tianjin, China
6 Regenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center For Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Scienc, Tianjin, China
7 Regenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center For Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Scienc, Tianjin, China
8 Regenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center For Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Scienc, Tianjin, China

Purpose: To explore a treatment strategy for refractory/relapsed(R/R) aplastic anemia (AA) with a prospective, single-center, open-label clinical trial (NCT07078721)

 

Methods: Single-unit unrelated cord blood transplantation (sUCBT) with total marrow irradiation (TMI), fludarabine (FLU), and melphalan (Mel) conditioning was administered to 11 patients with R/R AA to evaluate its efficacy.

Inclusion Criteria:Subjects suitable for enrollment in this study must meet all of the following criteria:(1) Age:18~50 years, regardless of gender. (2) Diagnosis of AA according to the guidelines of the British Society for Haematology. (3) ECOG score ≤2, HCT-CI index ≤2. (4) No HLA-identical sibling donor or no HLA-identical unrelated donor available.Study Protocol:

(1) Conditioning Regimen: Flu 30 mg/m²qd on Days -6, -5, -4, -3, -2; TMI 4 Gy qd on Day -2; Mel 100 mg/m² qd on Day -1.(2) Single Cord Blood Unit: HLA Matching: The cord blood unit should have an HLA match of ≥4/6, 5/8, 6/10 with the patient.(3) GVHD Prophylaxis: Cyclosporine and Mycophenolate mofetil are used in prophylaxis. Primary Endpoint:Event-free survival (EFS) at 12 months post-transplant.

 

Results: From July 2025 to July 2026, enrollment has been completed. The cohort included 4 males and 7 females, with a median age of 31 (19~49) years. 9 patients had severe AA (SAA) and 2 had very severe AA (vSAA). 9 patients had refractory AA and 2 had relapsed AA. The median time from diagnosis to UCBT was 92.23 (8.27~344.8) months. The median follow-up after UCBT was 126 (14~359) days. Baseline median blood counts were: absolute neutrophil count (ANC) 0.57 (0.22~1.45)×109/L, hemoglobin (HGB) 54 (31~79) g/L, platelets (PLT) 4 (1~16)×109/L, absolute reticulocyte count (ARC) 25.1 (4.2~69.9)×109/L. Median serum ferritin was 1038 (28.8~3453) μg/L. All cord blood units were HLA-matched with recipients at 4/6, 5/8, 6/10, and 7/12 loci. The median infused total nucleated cell (TNC) count after thawing was 2.35 (1.24~3.54)×107/kg, and the median infused CD34+ cell count was 1.84 (0.94~4.12)×105/kg.

 

The cord blood stem cell engraftment was achieved in rate 10/11(90.91%) patients; 1 patient experienced primary graft failure(the salvage second haploidentical PBSCT from the child to the father was successful). The median short tandem repeat (STR) chimerism was 55.74% (12.9~77.76%) on day +7, 99.70% (9.5~100%) on day +14, and 99.58% (0.22~100%) on day +21. Complete donor chimerism on day +14 was achieved in 90.91% of patients.

 

Hematopoietic reconstitution: The median time to neutrophil engraftment was 18 (13~36) days, erythroid engraftment 28 (14~42) days, platelet engraftment 31 (19~53) days. The engraftment rate on day +42 was 100% for both neutrophils and erythroid lineage, and the PLT engraftment rate on day +60 was 100%.

 

Graft-versus-host disease(GVHD) and other complications: Grade II~IV acute GVHD occurred in 18.2% (2/11) of patients, both grade III; Only 1 patient developed mild chronic GVHD. Infections occurred in 100% of patients from day -2 to day +24 after infusion; all grade 3, including 6 cases of sepsis. Menstruation resumed in 4 evaluable female patients.

 

Survival: The median follow-up was 126 (14~345) days. All 11 patients were alive, with no relapse, active infection, or moderate/severe cGVHD. EFS was 90.91%.

 

Conclusions TMI-based conditioning sUCBT provides a novel therapeutic option for R/R AA with promising clinical prospects.

Yuan Li: No relevant conflicts of interest to declare.